Free Trial
Tada emoji MarketBeat All Access — Now Just $5.00 for 5 Weeks

Immunome (IMNM) Financials

Immunome logo
$10.28 +0.34 (+3.42%)
Closing price 04:00 PM Eastern
Extended Trading
$10.09 -0.19 (-1.90%)
As of 05:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Immunome

Annual Income Statements for Immunome

This table shows Immunome's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -10 -18 -25 -38 -107 -293
Consolidated Net Income / (Loss)		 -10 -18 -25 -37 -107 -293
Net Income / (Loss) Continuing Operations		 -10 -18 -25 -37 -107 -293
Total Pre-Tax Income 		-10 -18 -25 -37 -107 -293
Total Operating Income		 -10 -12 -25 -37 -110 -306
Total Gross Profit		 0.00 0.00 0.00 0.00 14 9.04
Total Revenue		 0.00 0.00 0.00 0.00 14 9.04
Operating Revenue		 - - - 0.00 14 9.04
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 10 12 25 37 124 315
Selling, General & Admin Expense		 1.53 4.78 11 14 20 33
Research & Development Expense		 8.82 7.49 14 23 104 282
Total Other Income / (Expense), net		 -0.10 -5.58 0.49 0.01 2.72 13
Interest Expense		 0.10 0.04 0.01 -0.01 -2.72 -13
Basic Earnings per Share		 ($9.55) ($5.26) ($2.14) ($3.09) ($5.38) ($5.00)
Weighted Average Basic Shares Outstanding		 1.09M 3.39M 11.54M 12.13M 19.84M 58.64M
Diluted Earnings per Share		 ($9.55) ($5.26) ($2.14) ($3.09) ($5.38) ($5.00)
Weighted Average Diluted Shares Outstanding		 1.09M 3.39M 11.54M 12.13M 19.84M 58.64M
Weighted Average Basic & Diluted Shares Outstanding		 1.09M 3.39M 12.13M 12.22M 59.69M 86.95M

Quarterly Income Statements for Immunome

This table shows Immunome's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -9.16 -28 -4.27 -5.56 -4.35 -93 -129 -36 -47 -80 -42
Consolidated Net Income / (Loss)		 -8.53 -7.79 -4.27 -5.56 -4.35 -93 -129 -36 -47 -80 -42
Net Income / (Loss) Continuing Operations		 -8.53 -7.79 -4.27 -5.56 -4.35 -93 -129 -36 -47 -80 -42
Total Pre-Tax Income 		-8.53 -7.79 -4.27 -5.56 -4.35 -93 -129 -36 -47 -80 -42
Total Operating Income		 -8.53 -7.79 -4.47 -5.77 -4.63 -95 -132 -40 -51 -83 -45
Total Gross Profit		 0.00 - 2.36 4.26 3.57 3.83 1.03 2.36 2.91 2.74 2.93
Total Revenue		 0.00 - 2.36 4.26 3.57 3.83 1.03 2.36 2.91 2.74 2.93
Operating Revenue		 0.00 - 2.36 4.26 3.57 3.83 1.03 2.36 2.91 2.74 2.93
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 8.53 7.79 6.84 10 8.20 98 133 42 53 86 48
Selling, General & Admin Expense		 3.31 3.54 2.92 4.32 4.38 8.04 6.01 6.98 9.53 10 11
Research & Development Expense		 5.23 4.25 3.91 5.72 3.82 90 127 35 44 75 37
Total Other Income / (Expense), net		 0.00 0.00 0.20 0.22 0.29 2.02 2.81 3.89 3.42 2.72 3.00
Interest Expense		 -0.00 -0.00 -0.20 -0.22 -0.29 -2.02 -2.81 -3.89 -3.42 -2.72 -3.00
Basic Earnings per Share		 ($0.75) ($0.64) ($0.35) ($0.46) ($0.36) ($4.21) ($2.51) ($0.60) ($0.78) ($1.11) ($0.52)
Weighted Average Basic Shares Outstanding		 12.13M 12.13M 12.18M 12.20M 12.20M 19.84M 51.54M 59.94M 60.21M 58.64M 79.41M
Diluted Earnings per Share		 ($0.75) ($0.64) ($0.35) ($0.46) ($0.36) ($4.21) ($2.51) ($0.60) ($0.78) ($1.11) ($0.52)
Weighted Average Diluted Shares Outstanding		 12.13M 12.13M 12.18M 12.20M 12.20M 19.84M 51.54M 59.94M 60.21M 58.64M 79.41M
Weighted Average Basic & Diluted Shares Outstanding		 12.13M 12.22M 12.22M 12.20M 42.73M 59.69M 59.97M 60.05M 62.42M 86.95M 87.01M

Annual Cash Flow Statements for Immunome

This table details how cash moves in and out of Immunome's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 0.94 37 9.46 -29 78 45
Net Cash From Operating Activities		 -9.60 -12 -18 -29 -7.57 -111
Net Cash From Continuing Operating Activities		 -9.60 -12 -18 -29 -7.57 -111
Net Income / (Loss) Continuing Operations		 -10 -18 -25 -37 -107 -293
Consolidated Net Income / (Loss)		 -10 -18 -25 -37 -107 -293
Depreciation Expense		 0.62 0.76 0.76 0.42 0.46 1.57
Amortization Expense		 - - 0.00 0.21 -0.24 -2.36
Non-Cash Adjustments To Reconcile Net Income		 0.02 6.16 2.95 5.33 87 168
Changes in Operating Assets and Liabilities, net		 0.21 -1.21 2.78 2.24 12 15
Net Cash From Investing Activities		 -0.23 -0.59 -0.08 -0.25 -30 -85
Net Cash From Continuing Investing Activities		 -0.23 -0.59 -0.08 -0.25 -30 -85
Purchase of Property, Plant & Equipment		 -0.23 -0.59 -0.08 -0.25 -0.83 -7.17
Acquisitions		 - - - - 0.00 -46
Purchase of Investments		 - - - 0.00 -39 -187
Divestitures		 - - - 0.00 9.28 0.00
Sale and/or Maturity of Investments		 - - - - 0.00 155
Net Cash From Financing Activities		 11 50 28 0.03 116 241
Net Cash From Continuing Financing Activities		 11 50 28 0.03 116 241
Issuance of Debt		 6.80 0.50 - - 0.00 230
Issuance of Common Equity		 0.00 39 29 0.00 125 20
Other Financing Activities, net		 -0.22 -0.19 -0.80 0.03 -8.63 -9.47

Quarterly Cash Flow Statements for Immunome

This table details how cash moves in and out of Immunome's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Net Change in Cash & Equivalents		 -7.57 -6.76 24 -6.01 52 8.04 171 -104 -9.76 -12 114
Net Cash From Operating Activities		 -7.57 -6.68 24 -5.67 -8.61 -17 -11 -23 -34 -42 -53
Net Cash From Continuing Operating Activities		 -7.57 -6.68 24 -5.67 -8.61 -17 -11 -23 -34 -42 -53
Net Income / (Loss) Continuing Operations		 -8.53 -7.79 -4.27 -5.56 -4.35 -93 -129 -36 -47 -80 -42
Consolidated Net Income / (Loss)		 -8.53 -7.79 -4.27 -5.56 -4.35 -93 -129 -36 -47 -80 -42
Depreciation Expense		 0.10 0.10 0.09 0.10 0.11 0.15 0.16 0.55 0.41 0.45 0.61
Amortization Expense		 0.01 0.17 0.05 0.06 0.39 -0.74 -0.43 -0.23 -1.31 -0.39 -0.70
Non-Cash Adjustments To Reconcile Net Income		 1.34 1.36 1.16 1.03 1.09 84 114 9.50 12 33 5.64
Changes in Operating Assets and Liabilities, net		 -0.49 -0.51 27 -1.30 -5.85 -8.14 4.51 2.91 2.31 5.21 -17
Net Cash From Investing Activities		 - -0.07 -0.11 -0.34 -0.04 -30 -37 -82 24 9.76 5.09
Net Cash From Continuing Investing Activities		 - -0.07 -0.11 -0.34 -0.04 -30 -37 -82 24 9.76 5.09
Purchase of Property, Plant & Equipment		 - -0.07 -0.11 -0.34 -0.04 -0.35 -2.16 -2.34 -1.54 -1.13 -3.67
Acquisitions		 - - 0.00 - - - -35 -6.66 -4.36 -0.25 -6.25
Sale and/or Maturity of Investments		 - - - - - - 0.00 - 30 85 15
Net Cash From Financing Activities		 - - 0.03 - 61 55 219 0.69 0.31 20 162
Net Cash From Continuing Financing Activities		 - - 0.03 - 61 55 219 0.69 0.31 20 162
Issuance of Debt		 - - 0.00 - - - 230 - - - 173
Other Financing Activities, net		 - - 0.00 - -0.13 -8.50 -11 0.69 0.31 0.09 -10

Annual Balance Sheets for Immunome

This table presents Immunome's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 5.06 45 58 24 149 240
Total Current Assets		 3.12 43 57 23 145 221
Cash & Equivalents		 2.54 40 49 20 99 143
Short-Term Investments		 - - - 0.00 39 74
Prepaid Expenses		 0.58 3.13 7.41 2.33 6.56 4.04
Plant, Property, & Equipment, net		 1.70 1.53 0.86 0.68 2.07 10
Total Noncurrent Assets		 0.24 0.10 0.43 0.72 1.76 8.79
Other Noncurrent Operating Assets		 0.24 0.10 0.43 0.72 1.76 8.79
Total Liabilities & Shareholders' Equity		 5.06 45 58 24 149 240
Total Liabilities		 1.80 3.18 9.74 7.39 29 59
Total Current Liabilities		 1.67 3.04 9.73 7.33 22 54
Accounts Payable		 0.55 1.19 3.08 2.40 3.31 14
Accrued Expenses		 0.67 1.37 6.65 4.93 8.03 33
Current Deferred Revenue		 - - - 0.00 10 6.94
Total Noncurrent Liabilities		 0.13 0.14 0.01 0.06 6.83 4.77
Other Noncurrent Operating Liabilities		 0.11 - 0.01 0.06 1.34 4.77
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -36 41 48 17 120 181
Total Preferred & Common Equity		 -36 41 48 17 120 181
Preferred Stock		 - 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -36 41 48 17 120 181
Common Stock		 0.93 96 127 133 343 697
Retained Earnings		 -37 -54 -79 -116 -223 -516
Accumulated Other Comprehensive Income / (Loss)		 - - - 0.00 0.02 0.06

Quarterly Balance Sheets for Immunome

This table presents Immunome's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2022 Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025
Period end date 6/30/2022 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025
Total Assets		 39 31 48 41 93 320 296 257 343
Total Current Assets		 38 29 47 40 91 313 284 244 323
Cash & Equivalents		 35 27 44 38 91 270 165 156 258
Short-Term Investments		 - - - - - 40 113 85 60
Prepaid Expenses		 2.95 2.16 2.11 1.11 0.77 3.62 5.93 3.91 5.81
Plant, Property, & Equipment, net		 0.81 0.70 0.92 1.20 1.17 4.30 6.10 7.17 11
Total Noncurrent Assets		 0.61 0.60 0.66 0.71 0.58 2.13 5.84 5.69 8.61
Other Noncurrent Operating Assets		 0.61 0.60 0.66 0.71 0.58 2.13 5.84 5.69 8.61
Total Liabilities & Shareholders' Equity		 39 31 48 41 93 320 296 257 343
Total Liabilities		 8.74 7.46 34 32 87 34 42 42 36
Total Current Liabilities		 8.62 7.37 25 26 23 31 40 40 31
Accounts Payable		 5.26 3.14 3.31 3.70 2.79 7.18 7.05 3.52 9.13
Accrued Expenses		 3.36 4.23 3.31 5.03 3.37 11 20 26 18
Current Deferred Revenue		 - - 18 18 17 13 13 9.68 4.02
Total Noncurrent Liabilities		 0.12 0.09 9.42 5.71 64 3.41 2.48 2.46 4.77
Other Noncurrent Operating Liabilities		 0.12 0.09 0.00 0.00 61 1.21 2.48 2.46 4.77
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 - - 0.00
Total Equity & Noncontrolling Interests		 30 23 14 9.34 6.08 286 254 215 307
Total Preferred & Common Equity		 30 23 14 9.34 6.08 286 254 215 307
Preferred Stock		 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 30 23 14 9.34 6.08 286 254 215 307
Common Stock		 130 131 134 135 136 638 642 650 865
Retained Earnings		 -100 -108 -120 -126 -130 -352 -388 -436 -557
Accumulated Other Comprehensive Income / (Loss)		 - - - - - 0.00 0.00 0.07 -0.00

Annual Metrics And Ratios for Immunome

This table displays calculated financial ratios and metrics derived from Immunome's official financial filings.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% -35.50%
EBITDA Growth		 0.00% -75.12% -40.50% -51.47% -201.39% -180.47%
EBIT Growth		 0.00% -72.00% -38.78% -49.39% -196.82% -179.19%
NOPAT Growth		 0.00% -18.49% -105.56% -46.41% -196.82% -179.19%
Net Income Growth		 0.00% -70.79% -38.54% -49.31% -189.48% -174.29%
EPS Growth		 0.00% 44.92% 59.32% -44.39% -74.11% 7.06%
Operating Cash Flow Growth		 0.00% -26.40% -50.21% -57.41% 73.62% -1,363.98%
Free Cash Flow Firm Growth		 0.00% 0.00% -46.06% -59.81% -167.54% -216.01%
Invested Capital Growth		 0.00% 188.35% -150.22% -251.53% -397.55% -97.91%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 37.54% -10.74%
EBITDA Q/Q Growth		 0.00% 0.00% -16.58% 0.55% -406.06% 3.87%
EBIT Q/Q Growth		 0.00% 0.00% -15.25% 0.15% -383.28% 3.68%
NOPAT Q/Q Growth		 0.00% 0.00% -17.59% 0.15% -383.28% 3.68%
Net Income Q/Q Growth		 0.00% 0.00% -18.05% 0.18% -386.41% 4.06%
EPS Q/Q Growth		 0.00% 0.00% -137.74% 0.64% -197.24% 38.27%
Operating Cash Flow Q/Q Growth		 0.00% -40.26% -4.25% 0.42% -335.91% -28.54%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.52% -195.94% 30.33%
Invested Capital Q/Q Growth		 0.00% 0.00% 28.00% 8.11% 78.41% -43.27%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 100.00% 100.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% -779.81% -3,391.18%
Operating Margin		 0.00% 0.00% 0.00% 0.00% -781.35% -3,382.37%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% -781.35% -3,382.37%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% -761.92% -3,240.38%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.93% 100.21% 100.04% 99.99% 97.51% 95.80%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -319.98% -79.97% -55.20% -113.81% -156.45% -194.63%
Cash Return on Invested Capital (CROIC)		 0.00% -710.05% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% -126.93% -157.31%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% -123.77% -150.71%
Return on Common Equity (ROCE)		 3,492.87% -10.25% -55.20% -113.81% -156.45% -194.63%
Return on Equity Simple (ROE_SIMPLE)		 29.31% -43.14% -51.28% -221.56% -89.09% -161.71%
Net Operating Profit after Tax (NOPAT)		 -7.24 -8.58 -18 -26 -77 -214
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -546.95% -2,367.66%
Net Nonoperating Expense Percent (NNEP)		 -125.85% -44.27% -15.97% -31.82% -38.03% -44.40%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -63.96% -118.16%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 140.23% 364.51%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 741.13% 3,117.86%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 881.35% 3,482.37%
Earnings before Interest and Taxes (EBIT)		 -10 -18 -25 -37 -110 -306
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -9.73 -17 -24 -36 -109 -307
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 0.00 2.47 3.25 1.61 3.81 3.66
Price to Tangible Book Value (P/TBV)		 0.00 2.47 3.25 1.61 3.81 3.66
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 32.62 73.32
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 104.51 30.20 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 22.76 49.28
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.01 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.78 -0.94 -0.99 -1.07 -1.16 -1.18
Leverage Ratio		 1.55 1.11 1.14 1.26 1.26 1.29
Compound Leverage Factor		 1.56 1.11 1.14 1.26 1.23 1.24
Debt to Total Capital		 0.00% 1.19% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.87% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.32% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 1,191.61% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -1,091.61% 98.81% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 -0.03 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 2.30 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 -0.01 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 -0.06 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 4.58 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 -0.02 0.00 0.00 0.00 0.00
Altman Z-Score		 -3.49 17.30 7.31 -8.88 6.13 0.40
Noncontrolling Interest Sharing Ratio		 1,191.61% 87.19% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 1.88 14.12 5.82 3.09 6.63 4.08
Quick Ratio		 1.53 13.09 5.06 2.77 6.33 4.00
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -9.94 -15 -23 -62 -196
Operating Cash Flow to CapEx		 -4,120.17% -2,070.65% -23,070.89% -11,568.55% -910.71% -1,544.60%
Free Cash Flow to Firm to Interest Expense		 0.00 -261.60 -1,451.98 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -100.00 -319.32 -1,822.60 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -102.43 -334.74 -1,830.50 0.00 0.00 0.00
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.16 0.05
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 10.18 1.48
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 0.72 2.08 -1.04 -3.67 -18 -36
Invested Capital Turnover		 0.00 0.00 0.00 0.00 -1.28 -0.33
Increase / (Decrease) in Invested Capital		 0.00 1.36 -3.12 -2.63 -15 -18
Enterprise Value (EV)		 75 63 108 6.48 319 446
Market Capitalization		 39 102 157 27 457 663
Book Value per Share		 ($32.57) $3.92 $3.98 $1.37 $2.81 $2.90
Tangible Book Value per Share		 ($32.57) $3.92 $3.98 $1.37 $2.81 $2.90
Total Capital		 3.26 42 48 17 120 181
Total Debt		 0.00 0.50 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.13 0.00 0.00 0.00 0.00
Net Debt		 -2.54 -39 -49 -20 -138 -217
Capital Expenditures (CapEx)		 0.23 0.59 0.08 0.25 0.83 7.17
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.09 0.46 -2.32 -5.01 -15 -50
Debt-free Net Working Capital (DFNWC)		 1.46 40 47 15 123 167
Net Working Capital (NWC)		 1.46 40 47 15 123 167
Net Nonoperating Expense (NNE)		 3.20 9.25 7.07 11 30 79
Net Nonoperating Obligations (NNO)		 -2.54 -39 -49 -20 -138 -217
Total Depreciation and Amortization (D&A)		 0.62 0.76 0.76 0.63 0.22 -0.80
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% -108.92% -556.03%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 876.54% 1,847.49%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 876.54% 1,847.49%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($5.26) ($2.14) ($3.09) ($5.38) ($5.00)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 10.66M 11.54M 12.13M 19.84M 58.64M
Adjusted Diluted Earnings per Share		 $0.00 ($5.26) ($2.14) ($3.09) ($5.38) ($5.00)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 10.66M 11.54M 12.13M 19.84M 58.64M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($5.26) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 3.39M 12.13M 12.22M 59.69M 86.95M
Normalized Net Operating Profit after Tax (NOPAT)		 -7.24 -8.58 -18 -26 -77 -214
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% -546.95% -2,367.66%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% -761.92% -3,240.38%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 -107.79 -468.39 -2,470.10 0.00 0.00 0.00
NOPAT to Interest Expense		 -75.45 -225.86 -1,764.28 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -110.22 -483.82 -2,478.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -77.88 -241.28 -1,772.18 0.00 0.00 0.00
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.34% -0.27% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Immunome

This table displays calculated financial ratios and metrics derived from Immunome's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -56.47% -44.55% -18.37% -28.44% 184.35%
EBITDA Growth		 -13.31% 2.58% 62.47% 36.22% 50.89% -1,165.31% -2,966.71% -606.70% -1,143.63% 12.95% 66.26%
EBIT Growth		 -10.59% 0.73% 61.64% 35.32% 45.71% -1,115.53% -2,859.05% -593.04% -990.48% 12.34% 66.26%
NOPAT Growth		 -10.50% 0.73% 61.64% 35.32% 45.71% -1,115.53% -2,859.05% -593.04% -990.48% 12.34% 66.26%
Net Income Growth		 -10.53% 0.84% 63.36% 37.73% 49.08% -1,089.75% -2,932.60% -550.03% -984.00% 13.37% 67.84%
EPS Growth		 -15.38% 3.03% 63.54% 37.84% 52.00% -557.81% -617.14% -30.43% -116.67% 73.63% 79.28%
Operating Cash Flow Growth		 -82.65% 1.79% 479.12% 29.68% -13.78% -161.24% -146.21% -312.79% -296.65% -140.91% -374.98%
Free Cash Flow Firm Growth		 68.58% -19.30% 2,244.51% 1,999.00% 2,354.59% -1,728.99% -541.59% -257.61% -222.47% 22.19% 54.38%
Invested Capital Growth		 -175.45% -251.53% -510.63% -565.10% -2,017.30% -397.55% 21.03% 15.69% 70.17% -97.91% 57.75%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 80.33% -16.37% 7.32% -73.11% 129.74% 23.10% -5.91% 6.87%
EBITDA Q/Q Growth		 4.37% 10.61% 42.57% -29.91% 26.37% -2,203.26% -39.69% 70.06% -29.57% -61.23% 46.05%
EBIT Q/Q Growth		 4.39% 8.75% 42.58% -29.12% 19.75% -1,943.02% -39.77% 69.76% -26.28% -64.23% 46.20%
NOPAT Q/Q Growth		 4.39% 8.75% 42.58% -29.12% 19.75% -1,943.02% -39.77% 69.76% -26.28% -64.23% 46.20%
Net Income Q/Q Growth		 4.38% 8.75% 45.16% -30.14% 21.81% -2,031.97% -39.79% 72.10% -30.39% -70.38% 48.11%
EPS Q/Q Growth		 -1.35% 14.67% 45.31% -31.43% 21.74% -1,069.44% 40.38% 76.10% -30.00% -42.31% 53.15%
Operating Cash Flow Q/Q Growth		 6.07% 11.73% 461.71% -123.45% -51.98% -102.68% 36.02% -109.46% -46.03% -23.10% -26.14%
Free Cash Flow Firm Q/Q Growth		 -215.18% 17.64% 893.91% -7.86% 274.20% -166.82% -91.68% 67.11% -190.78% 57.55% -12.39%
Invested Capital Q/Q Growth		 8.65% 8.11% -732.75% 4.86% -190.82% 78.41% -32.17% -1.58% -2.89% -43.27% 71.78%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% 0.00% -182.87% -131.74% -115.99% -2,489.28% -12,883.77% -1,678.85% -1,767.15% -3,028.16% -1,528.64%
Operating Margin		 0.00% 0.00% -189.13% -135.42% -129.96% -2,473.94% -12,857.05% -1,692.43% -1,736.15% -3,030.31% -1,525.50%
EBIT Margin		 0.00% 0.00% -189.13% -135.42% -129.96% -2,473.94% -12,857.05% -1,692.43% -1,736.15% -3,030.31% -1,525.50%
Profit (Net Income) Margin		 0.00% 0.00% -180.63% -130.35% -121.88% -2,421.17% -12,584.26% -1,528.00% -1,618.56% -2,930.94% -1,423.10%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 99.99% 99.99% 95.50% 96.26% 93.78% 97.87% 97.88% 90.28% 93.23% 96.72% 93.29%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -94.92% -113.81% -114.09% -132.00% -150.60% -156.45% -154.98% -199.56% -276.36% -194.63% -69.21%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% -9.33% -22.31% -21.41% -401.88% -886.55% -108.11% -100.47% -140.94% -50.38%
Return on Assets (ROA)		 0.00% 0.00% -8.91% -21.47% -20.08% -393.31% -867.74% -97.60% -93.67% -136.32% -47.00%
Return on Common Equity (ROCE)		 -94.92% -113.81% -114.09% -132.00% -150.60% -156.45% -154.98% -199.56% -276.36% -194.63% -69.21%
Return on Equity Simple (ROE_SIMPLE)		 -160.12% 0.00% -212.91% -280.00% -361.39% 0.00% -81.25% -103.45% -142.08% 0.00% -66.78%
Net Operating Profit after Tax (NOPAT)		 -5.97 -5.45 -3.13 -4.04 -3.24 -66 -93 -28 -35 -58 -31
NOPAT Margin		 0.00% 0.00% -132.39% -94.79% -90.97% -1,731.76% -8,999.93% -1,184.70% -1,215.31% -2,121.22% -1,067.85%
Net Nonoperating Expense Percent (NNEP)		 -6.14% -6.71% -2.61% -4.15% -1.87% -33.29% -20.83% -5.12% -7.10% -12.47% -3.32%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -55.27% - - - -32.06% -10.17%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 123.60% 101.34% 122.72% 210.14% 583.58% 295.18% 327.35% 381.52% 365.35%
R&D to Revenue		 0.00% 0.00% 165.52% 134.08% 107.24% 2,363.80% 12,373.47% 1,497.25% 1,508.80% 2,748.79% 1,260.15%
Operating Expenses to Revenue		 0.00% 0.00% 289.13% 235.42% 229.96% 2,573.94% 12,957.05% 1,792.43% 1,836.15% 3,130.31% 1,625.50%
Earnings before Interest and Taxes (EBIT)		 -8.53 -7.79 -4.47 -5.77 -4.63 -95 -132 -40 -51 -83 -45
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -8.42 -7.53 -4.32 -5.62 -4.14 -95 -133 -40 -51 -83 -45
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.33 1.61 4.40 10.35 16.77 3.81 5.16 2.86 4.09 3.66 1.91
Price to Tangible Book Value (P/TBV)		 2.33 1.61 4.40 10.35 16.77 3.81 5.16 2.86 4.09 3.66 1.91
Price to Revenue (P/Rev)		 0.00 0.00 25.78 14.58 10.00 32.62 116.16 67.29 86.68 73.32 53.50
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 6.99 8.78 1.10 22.76 91.74 41.48 62.97 49.28 24.49
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 8.89 13.69 3.51 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 3.48 9.53 0.17 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.07 -1.07 -1.69 -1.84 -4.04 -1.16 -1.18 -1.20 -1.50 -1.18 -1.06
Leverage Ratio		 1.20 1.26 1.85 2.03 4.24 1.26 1.23 1.28 1.58 1.29 1.12
Compound Leverage Factor		 1.20 1.26 1.77 1.95 3.98 1.24 1.20 1.16 1.48 1.25 1.04
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -0.69 -4.88 -2.15 -2.36 -0.43 6.46 24.05 9.02 10.52 3.46 8.22
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.97 3.09 1.87 1.50 3.96 6.63 10.18 7.12 6.17 4.08 10.49
Quick Ratio		 3.67 2.77 1.79 1.46 3.92 6.33 10.07 6.98 6.07 4.00 10.30
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -3.43 -2.82 22 21 77 -52 -99 -33 -95 -40 -45
Operating Cash Flow to CapEx		 0.00% -9,281.94% 22,804.72% -1,667.06% -23,927.78% -5,002.58% -516.17% -998.17% -2,220.08% -3,735.35% -1,447.61%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.05 0.16 0.16 0.16 0.07 0.06 0.06 0.05 0.03
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 2.83 6.59 10.87 10.18 4.86 2.95 2.43 1.48 1.43
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -3.99 -3.67 -31 -29 -85 -18 -24 -25 -25 -36 -10
Invested Capital Turnover		 0.00 0.00 -0.13 -0.40 -0.23 -1.28 -0.46 -0.40 -0.18 -0.33 -0.64
Increase / (Decrease) in Invested Capital		 -2.54 -2.63 -26 -25 -81 -15 6.43 4.56 59 -18 14
Enterprise Value (EV)		 27 6.48 17 58 11 319 1,164 447 638 446 268
Market Capitalization		 54 27 61 97 102 457 1,473 726 878 663 585
Book Value per Share		 $1.90 $1.37 $1.13 $0.76 $0.50 $2.81 $4.78 $4.23 $3.58 $2.90 $3.53
Tangible Book Value per Share		 $1.90 $1.37 $1.13 $0.76 $0.50 $2.81 $4.78 $4.23 $3.58 $2.90 $3.53
Total Capital		 23 17 14 9.34 6.08 120 286 254 215 181 307
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -27 -20 -44 -38 -91 -138 -310 -278 -240 -217 -317
Capital Expenditures (CapEx)		 0.00 0.07 0.11 0.34 0.04 0.35 2.16 2.34 1.54 1.13 3.67
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -5.21 -5.01 -23 -25 -22 -15 -27 -34 -36 -50 -25
Debt-free Net Working Capital (DFNWC)		 22 15 22 13 68 123 283 244 205 167 292
Net Working Capital (NWC)		 22 15 22 13 68 123 283 244 205 167 292
Net Nonoperating Expense (NNE)		 2.56 2.34 1.14 1.52 1.10 26 37 8.12 12 22 10
Net Nonoperating Obligations (NNO)		 -27 -20 -44 -38 -91 -138 -310 -278 -240 -217 -317
Total Depreciation and Amortization (D&A)		 0.11 0.26 0.15 0.16 0.50 -0.59 -0.28 0.32 -0.90 0.06 -0.09
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% -961.04% -381.50% -219.17% -108.92% -214.05% -314.99% -351.64% -556.03% -228.47%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 918.15% 198.19% 670.16% 876.54% 2,227.85% 2,266.17% 2,019.07% 1,847.49% 2,672.64%
Net Working Capital to Revenue		 0.00% 0.00% 918.15% 198.19% 670.16% 876.54% 2,227.85% 2,266.17% 2,019.07% 1,847.49% 2,672.64%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.75) ($0.64) ($0.35) ($0.46) ($0.36) ($4.21) ($2.51) ($0.60) ($0.78) ($1.11) ($0.52)
Adjusted Weighted Average Basic Shares Outstanding		 12.13M 12.13M 12.18M 12.20M 12.20M 19.84M 51.54M 59.94M 60.21M 58.64M 79.41M
Adjusted Diluted Earnings per Share		 ($0.75) ($0.64) ($0.35) ($0.46) ($0.36) ($4.21) ($2.51) ($0.60) ($0.78) ($1.11) ($0.52)
Adjusted Weighted Average Diluted Shares Outstanding		 12.13M 12.13M 12.18M 12.20M 12.20M 19.84M 51.54M 59.94M 60.21M 58.64M 79.41M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 12.13M 12.22M 12.22M 12.20M 42.73M 59.69M 59.97M 60.05M 62.42M 86.95M 87.01M
Normalized Net Operating Profit after Tax (NOPAT)		 -5.97 -5.45 -3.13 -4.04 -3.24 -66 -93 -28 -35 -58 -31
Normalized NOPAT Margin		 0.00% 0.00% -132.39% -94.79% -90.97% -1,731.76% -8,999.93% -1,184.70% -1,215.31% -2,121.22% -1,067.85%
Pre Tax Income Margin		 0.00% 0.00% -180.63% -130.35% -121.88% -2,421.17% -12,584.26% -1,528.00% -1,618.56% -2,930.94% -1,423.10%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Key Financial Trends

Immunome Inc. (NASDAQ: IMNM) reported financial results spanning from Q2 2022 through Q1 2025, reflecting significant trends in revenue, expenses, net income, cash flow, and balance sheet strength. Here is an analysis highlighting key positive, neutral, and negative aspects based on the company's recent financial statements.

  • The company exhibited steady revenue growth over the last several quarters, with operating revenue increasing from $0 in Q3 2022 to $2.93 million in Q1 2025, signaling growing commercial activity.
  • Cash and equivalents have substantially increased over the period, from approximately $27 million in Q3 2022 to $257.6 million in Q1 2025, boosting liquidity.
  • Net cash from financing activities in recent quarters, especially Q1 2025, showed strong capital inflows, with $162.2 million raised, primarily through issuance of debt and equity, supporting funding needs.
  • Decrease in research & development expense from a peak of $127.3 million in Q1 2024 down to $36.87 million in Q1 2025 indicates better cost control or completion of major development phases.
  • Gross profit has been positive and stable, with gross margins effectively 100% due to zero cost of revenue reported, illustrating low direct cost structure so far.
  • Net income remains negative across all quarters, reflecting ongoing investment in R&D and operating expenses aligned with early-stage biotech dynamics.
  • Operating expenses remain high, with total operating expenses still exceeding $47 million in Q1 2025, which is typical given the company's developmental status and pipeline investment needs.
  • Accounts payable and accrued expenses increased seasonally but remain manageable relative to cash balances.
  • Weighted average shares outstanding have increased significantly due to equity raises, diluting EPS but providing vital capital.
  • Despite large net losses, depictions of non-cash adjustments and changes in working capital largely influence cash flow variances each quarter.
  • Immunome continues to report substantial quarterly net losses, hitting -$41.64 million in Q1 2025, though reduced from -$129.49 million in Q1 2024, showing profitability remains a distant goal.
  • Significant cash used in operating activities persists, with negative net cash from operations at -$53.1 million in Q1 2025, highlighting ongoing burn rate concerns.
  • R&D expenses, although reduced, remain very high relative to revenue, implying continued reliance on external financing.
  • Total liabilities, while stable, are increasing in absolute terms and may pressure balance sheet if cash burn continues.
  • Diluted earnings per share remain negative throughout all reported quarters, with -$0.52 per share in Q1 2025, indicating no earnings profitability yet.

In summary, Immunome shows promising revenue growth and strengthened liquidity, driven by substantial capital raises. However, the company is still in an investment phase with persistent net losses and high operating expenses, primarily driven by research and development activities. Investors should weigh the growth potential against the ongoing cash burn and dilution risks typical of clinical-stage biotechs.

08/15/25 05:44 PMAI Generated. May Contain Errors.

Frequently Asked Questions About Immunome's Financials

When does Immunome's fiscal year end?

According to the most recent income statement we have on file, Immunome's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Immunome's net income changed over the last 5 years?

Immunome's net income appears to be on an upward trend, with a most recent value of -$292.96 million in 2024, rising from -$10.44 million in 2019. The previous period was -$106.81 million in 2023. See Immunome's forecast for analyst expectations on what’s next for the company.

What is Immunome's operating income?
Immunome's total operating income in 2024 was -$305.80 million, based on the following breakdown:
  • Total Gross Profit: $9.04 million
  • Total Operating Expenses: $314.84 million
How has Immunome's revenue changed over the last 5 years?

Over the last 5 years, Immunome's total revenue changed from $0.00 in 2019 to $9.04 million in 2024, a change of 904,100,000.0%.

How much debt does Immunome have?

Immunome's total liabilities were at $59.08 million at the end of 2024, a 106.1% increase from 2023, and a 3,189.3% increase since 2019.

How much cash does Immunome have?

In the past 5 years, Immunome's cash and equivalents has ranged from $2.54 million in 2019 to $143.35 million in 2024, and is currently $143.35 million as of their latest financial filing in 2024.

How has Immunome's book value per share changed over the last 5 years?

Over the last 5 years, Immunome's book value per share changed from -32.57 in 2019 to 2.90 in 2024, a change of -108.9%.


Related Companies

This page (NASDAQ:IMNM) was last updated on 8/15/2025 by MarketBeat.com Staff
From Our Partners
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...
Porter & Company | Sponsored
Alex’s “Next Magnificent Seven” stocks
The original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...
The Oxford Club | Sponsored
The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Something big is brewing in Washington. According to my research, an executive order from President Trump c...
Weiss Ratings | Sponsored
GENIUS Act: Cancel Your Money?
A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...
Priority Gold | Sponsored
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsored
BONUS GUIDE - Ben Stein Prepares For the Next Financial Crisis
With inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...
Goldco Precious Metals | Sponsored
Elon’s Secret Social Security Bombshell
To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...
Banyan Hill Publishing | Sponsored
Trump set to Boost Social Security Checks by 400%?
If you're collecting or planning to collect social security... You should see this presentation about Presi...
InvestorPlace | Sponsored